First Eagle Investment Management
VNDA icon

First Eagle Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

First Eagle Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-975,000
Closed -$7.88M – 380
2013
Q2 		$7.88M Buy
+975,000
New +$6.57M 0.02% 179

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

First Eagle Investment Management's VNDA Position: Q3 2013 in Review

First Eagle Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2013, closing a stake of 975,000 shares — an estimated $7.88M sold.

First Eagle Investment Management first reported a position in VNDA in Q2 2013 and held it in 1 quarter. The position peaked at $7.88M in Q2 2013. 99 funds tracked by Wall St. Rank hold VNDA as of Q3 2013.

  • First Eagle Investment Management reported no remaining Vanda Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • First Eagle Investment Management sold 975,000 Vanda Pharmaceuticals shares in Q3 2013, an estimated $7.88M.
  • First Eagle Investment Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • First Eagle Investment Management's Vanda Pharmaceuticals position peaked at $7.88M in Q2 2013.
  • 99 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2013.

Based on First Eagle Investment Management's 13F filing for Q3 2013, filed 13 Nov 2013.